Implementation of risk-sharing agreement in patients with lung cancer treated with immunotherapy based on RWD in the Czech Republic

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F23%3A00133110" target="_blank" >RIV/00216224:14110/23:00133110 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S109830152304634X?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S109830152304634X?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jval.2023.09.1504" target="_blank" >10.1016/j.jval.2023.09.1504</a>

Result language
angličtina
Original language name
Implementation of risk-sharing agreement in patients with lung cancer treated with immunotherapy based on RWD in the Czech Republic
Original language description
This analysis aimed to assess the impact of risk-sharing agreements on budgetary considerations and immunotherapy treatment outcomes for locally advanced and metastatic NSCLC in the Czech Republic.
Czech name
—
Czech description
—

Project
<a href="/en/project/LM2023049" target="_blank" >LM2023049: Czech National Node of the European Clinical Research Infrastructures Network</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach

Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Result description